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Abstract
Background
The World Health Organization (WHO) 2010 guidelines for intensified tuberculosis (TB)
case finding (ICF) among people living with HIV (PLHIV) includes a recommendation that
PLHIV receive routine TB screening. Since 2005, the Rwandan Ministry of Health has been
using a five-question screening tool. Our study objective was to assess the operating char-
acteristics of the tool designed to identify PLHIV with presumptive TB as measured against
a composite reference standard, including bacteriologically confirmed TB.
Methods
In a cross-sectional study, the TB screening tool was routinely administered at enrolment in
outpatient HIV care and treatment services at seven public health facilities. From March to
September 2011, study enrollees were examined for TB disease irrespective of TB screen-
ing outcome. The examination consisted of a chest radiograph (CXR), three sputum
smears (SS), sputum culture (SC) and polymerase chain reaction line-probe assay (Hain
test). PLHIV were classified as having “laboratory-confirmed TB” with positive results on
SS for acid-fast bacilli, SC on Lowenstein-Jensen medium, or a Hain test.
Results
Overall, 1,767 patients were enrolled and screened of which; 1,017 (57.6%) were female,
median age was 33 (IQR, 27–41), and median CD4+ cell count was 385 (IQR, 229–563)
cells/mm3. Of the patients screened, 138 (7.8%) were diagnosed with TB of which; 125
(90.5%) were laboratory-confirmed pulmonary TB. Of 404 (22.9%) patients who screened
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positive and 1,363 (77.1%) who screened negative, 79 (19.5%) and 59 (4.3%), respec-
tively, were diagnosed with TB. For laboratory-confirmed TB, the tool had a sensitivity of
54.4% (95% CI 45.3–63.3), specificity of 79.5% (95% CI 77.5–81.5), PPV of 16.8% and
NPV of 95.8%.
Conclusion
TB prevalence among PLHIV newly enrolling into HIV care and treatment was 65 times
greater than the overall population prevalence. However, the performance of the tool was
poorer than the predicted performance of the WHO recommended TB screening questions.
Introduction
Tuberculosis (TB) alongside HIV remains a leading cause of morbidity and mortality world-
wide. In 2014, there were an estimated 9.6 million new cases of TB and 1.5 million deaths from
TB globally. Overall, 12% of TB cases were among people living with Human Immunodefi-
ciency Virus (HIV). There has been important progress worldwide in implementing TB/HIV
collaborative activities and the numbers of people in HIV care and treatment services screened
for TB increased by 27% from 5.5 million to 7.0 million from 2013 to 2014. [1]
In Rwanda, the TB/HIV syndemic remains a public health priority. In 2014, the TB inci-
dence rate in Rwanda was estimated at 63/100,000 population, with a case detection rate of
81%. Among people with TB tested for HIV, the prevalence was 25%.[1,2] Recent data from
the national TB prevalence survey in Rwanda conducted in 2012 estimated a prevalence of
bacteriologically confirmedTB of 119.3 per 100,000 population (95%CI 78.8–159.9). [3]
In 2005, the Rwandan Ministry of Health (MOH) responded to the growing TB/HIV syn-
demic by developing a national policy on TB/HIV collaborative programs,[4] establishing a
TB/HIVworking group (TB/HIVWG), and revised program guidelines. The national policy
included guidelines for developing “one-stop” TB/HIV services including HIV counseling, test-
ing, and ARV treatment of people with TB testing positive for HIV through the TB clinic.
“One-stop” services also included systematic screening for TB disease among all people living
with HIV (PLHIV).
TheWorld Health Organization (WHO) 2010 guidelines for intensified tuberculosis (TB)
case finding (ICF) among people living with HIV (PLHIV) includes a recommendation that
PLHIV receive routine TB screening. Screening for TB disease among PLHIV is recommended
to increase early detection and initiation of anti-TB treatment, and to prevent ongoing trans-
mission in order to ultimately reduce TB-associatedmorbidity and mortality in the population.
Regular TB screening is important at any stage of HIV-associated immunodeficiency, since
HIV is a powerful risk factor for progression from latent TB infection (LTBI) to TB disease. TB
screening remains important even after patients start antiretroviral therapy (ART) because
PLHIV remain at increased risk of developing TB after initiating ART.[5] Similarly, TB screen-
ing among PLHIV is important to rule out TB disease before initiating Isoniazid Preventive
Therapy (IPT) to prevent or treat LTBI and to subsequently avoid the risk of Isoniazid resis-
tance due to inadvertent monotherapy.
In 2005, the Rwandan MOH began using a five-question symptom-based screening tool
including cough two weeks, fever three weeks, weight-loss of three kg over four weeks,
night sweats three weeks, and contact with someone known to have TB. In 2011, 93% of
patients newly enrolled in HIV care and treatment at 403 facilities were screened for TB.[6]
We aimed to assess the operating characteristics of the Rwandan TB screening tool designed to
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PLOS ONE | DOI:10.1371/journal.pone.0163462 September 29, 2016 2 / 14
Competing Interests: The authors have declared
that no competing interests exist.
identify PLHIV with presumptive TB as measured against a composite reference standard,
including bacteriologically confirmedTB.
Methods
Study Setting and Design
This validation study employed a cross-sectional design to assess the operating characteristics
of a TB screening tool that was being implemented as a part of routine clinical practice. PLHIV
attending an outpatient HIV care and treatment program at seven health facilities in Rwanda
were screened for TB using the screening tool upon enrollment into HIV care. These seven
health facilities (five district hospitals [DH] and two health centers [HC]) were selected because
they were the largest HIV treatment sites based on monthly patient enrollment trends. These
health facilities also represented outpatient HIV care and treatment sites that provided varying
levels of TB diagnostic and treatment services in rural and urban health facilities in Rwanda.
The required sample size was determined to be 1,460 patients, assuming a TB prevalence of
5% among PLHIV newly enrolled into HIV care and treatment,[7] an alpha of 0.05% and
power of 80% to detect a minimum difference of 2.5% in sensitivity between the screening
questionnaire and reference standard. The study sample size was a priori increased by 20% to
1,752 to account for anticipated lost samples, breakage, and contamination.
Study Population
Study participants included PLHIV age 21 years, and newly enrolled or transferred-in to
HIV care and treatment services at the seven selected sites. For this study, a “newly enrolled”
patient was defined as a patient who had undergone HIV testing with a positive test result,
CD4+ cell count testing and completed clinical evaluation. Patients were defined as trans-
ferred-in if they were referred from an HIV care and treatment clinic other than one of the
seven participating study sites. Pregnant women were included in the study. Patients were
excluded if they were hospitalized, currently receiving treatment for TB, or awaiting results of
an evaluation for TB.
Study Procedures
Enrollment. Patients newly registered and transferring into HIV care and treatment at the
seven sites were referred by clinic staff to the study coordinator based at each health facility.
Patients were included if they met eligibility criteria and provided written informed consent.
Screening tool. All patients enrolled in the study were screened for TB, using the TB
screening tool, by a trained nurse or doctor, as part of their routine care. The screening tool
consisted of five TB symptom- and contact-based questions including cough (both any cough
and cough for two weeks or more), night sweats for three weeks or more, weight loss of three
kilograms or more in the previous four weeks, fever for three weeks or more and close contact
with a known TB case. Any patient who replied ‘yes’ to at least one of the five questions was
considered to have screened positive and presumed to have TB. “Any cough” was not included
as an element in the national screening tool but was added for study purposes.
Diagnostic testing. All patients, regardless of positive or negative responses to the screen-
ing tool, provided three sputum samples (same day on the spot, next day early morning, and
spot) which were then processed for smear microscopy for acid-fast bacilli (AFB) at the health
facility laboratory. Patients who were unable to produce sputum spontaneously had sputum
induced with nebulized hypertonic saline. Furthermore, using triple packaging, one of the
three sputum samples, usually the same day spot sample, was sent to the National Reference
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Laboratory (NRL) located in Kigali for culture on solid media (Lowenstein Jensen) and further
testing. Each patient also had a Posterior-Anterior (PA) and lateral chest radiograph taken.
Chest radiographs were interpreted by two independent readers who were blinded to the
results of the TB screening tool. In case of discordance, the two radiologists re-interpreted the
radiograph together to reach a consensus.
Laboratoryprocedures. At the NRL, the samples were processed by use of N-Acetyl-L-
cysteine and sodium hydroxide (NALC–NaOH), followed by centrifugation and then were re-
suspended in 1.5 ml of phosphate. A portion of the sediment was stained and tested by AFB-
smear microscopy (Auramine O staining). A second portion was cultured on solid Löwen-
stein–Jensen (LJ) media. Quality assurance of TB microscopy was ensured through the national
system. Sputum slides from health centers were re-read by the laboratory technician at the dis-
trict hospital. NRL staff supervisedhospital-based testing and all discordant slides from the HC
level.
Indirect drug-susceptibility testing (DST) using the proportionmethod on LJ solid medium
was performed. Results of all smears, cultures and DST were delivered to the respective health
facility-based service for use in patient care. IfM. tuberculosis did not grow by eight weeks, the
culture result was read as negative, and if the diagnosis of TB was still entertained, it was man-
aged as culture-negative.
For all sputum collected for this study, additional diagnostic testing was planned to identify
M. tuberculosis, usingMPT64 antigen detection (Capilia TB1, Tauns Laboratories) or with
the line-probe assay with the use of the GenotypeMTBDR Plus assay (Hain Lifescience).How-
ever, not all study samples were tested using Capilia or Hain because of stock-outs.
Additional diagnostic testing. If a patient was clinically suspected of TB and required
additional evaluation beyond that offered in the study, he or she proceededwith further TB
assessment according to the national TB diagnostic guidelines.
Definition of composite reference standard for diagnosticM tuberculosis. Diagnosing
TB can be complicated, and therefore an inclusive approach was taken. Based on a combina-
tion of laboratory tests and chest radiograph results, we defined cases of TB as either lab- con-
firmed or probable, and classified them based on site of disease as either pulmonary or
extrapulmonary (Table 1).[8]
Table 1. TB Case Definitions.
For study purposes, the following case definitions were applied:
Laboratory-Confirmed
Pulmonary TB
One or more sputum smears positive for AFB or Sputum culture positive
for M. tuberculosis by Lowenstein Jensen (growth of two or more
colonies on solid media characterizing M. tuberculosis); or Hain positive;
or Capillia with M. tuberculosis identified, if done.
Probable Pulmonary TB Chest radiograph suggestive of TB after two series of three smears
negative on microscopy, negative culture and negative HAIN, and no
response to seven days of broad spectrum antibiotics. The CXR findings
can be of classical pattern (upper lobe, bilateral infiltrates, cavitation,
pulmonary fibrosis and shrinkage) or atypical pattern (interstitial
infiltrates especially lower zones, intrathoracic lymphadenopathy, no
cavitation and no abnormalities).
Laboratory-Confirmed extra-
pulmonary TB
M. tuberculosis isolated from relevant site (e.g. lymph node, pleura,
pericardium, peritoneum).
Probable extra-pulmonary TB
[9]
Other diagnostic evidence of TB (caseation or granulomata or
characteristic cerebrospinal fluid (CSF) changes). The CSF looks clear.
The white cell count is less than 500 per mm3 with predominantly
lymphocytes (or early in the course of infection, predominantly
polymorphs). Protein level is high (0.6-2g/l) and the glucose low (less
than 50% of glycaemia simultaneously measured).
doi:10.1371/journal.pone.0163462.t001
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Data analysis. Data analysis was conducted using STATA Version 12 (Copyright 1984–
2007 StataCorp TXUSA). Baseline characteristics are presented by means and medians as
appropriate for parametric and non-parametric data; ANOVA/ Student’s T-test and Kruskil-
Wallis / Mann Whitney U test were used to compare groups (TB confirmed, TB probable and
TB negative, etc.). Comparisons of the statistical significance of differences between categorical
data were done using the chi-square test.
Operating characteristics, including sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) with 95% CI and receiver operating curves (ROC), using a
logisticalmodel, were calculated for the TB screening tool (five screening questions together)
and each question separately. Operating characteristics of the screening tool were determined
based on the composite reference standard for confirmedTB cases and then confirmed and
probable TB cases combined (which included those diagnosed by radiography).
Subgroup analysis on the added diagnostic value of the chest radiographs was completed
using sensitivity and specificity compared to the composite reference standard for TB con-
firmed cases only (the probable cases were removed from this analysis as radiography was part
of the case definition/composite reference standard).
Analyses were stratified by factors affecting operating characteristics (male versus female,
urban versus rural areas, health center versus district/referral hospital, number of cases screened
per site—above versus below the median, and CD4+ cell count<200 vs200 cells/mm3).
Ethical issues. Study nurses obtained a signed consent form in Kinyarwanda from each
study participant. There was no compensation for participants who screened positive for TB
because all diagnostic follow-up was part of routine care. However, patients who screened neg-
ative were compensated for travel (3,000 RWF, equivalent of 5.5 USD) because of the addi-
tional health facility visits required to undergo diagnostic evaluation per the protocol.
This study was approved by the National AIDS Commission and Rwanda National Ethics
Commission in Rwanda, and the Columbia University Institutional ReviewBoard at Columbia
University Medical Center. The study was determined to be non-research by CDCAtlanta
based on the role of CDC investigators.
Results
Baseline Characteristics
A total of 2,928 PLHIV sought HIV care and treatment at the seven study sites fromMarch 1st,
2010 to September 16, 2011. Of these, 2,416 (82.5%) patients were referred to study staff. (Fig
1) Of those referred, 485 patients were excluded because they did not meet inclusion criteria:
190 (39.2%) were less than 21 years old, 49 (10.1%) were receiving anti-TB treatment, 31
(6.4%) were hospitalized, 164 (33.8%) refused participation, and for 51 (10.5%) the reason was
not documented. In total, 65.9% (1,931/2,928) of the patients who sought HIV care were
enrolled in the study, of whom 11 (0.6%) did not have documented screening results, 18 (0.9%)
patients were excluded retrospectively because they were infected by mycobacteria other than
TB (MOT) and 135 (7.0%) were removed from the analysis after enrollment in the study
because of data quality issues and high levels of missing data.
Among the 1,767 participants, seven were transferred-in from other HIV care and treat-
ment sites and were currently receivingART; 937 (53.0%) were from Kigali, with the remainder
from outside Kigali. (Table 2) The median age among the study population was 33 years (inter-
quartile range [IQR] 27–41), and 1,017 (57.6%) of the patients were female. Based on clinical
staging of HIV disease, 202 (11.7%) participants were classified as WHO stage III or IV. The
median CD4+ cell count at enrollment was 385 cells/μL (IQR 229–563). Among 138 confirmed
and probable TB cases, 62 (44.9%) were female, 57 (41.3%) had a CD4+ cell count<200 cells/
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μL and 23 (16.6%) were WHO stage III and IV. Kigali sites accounted for 74 (53.6%) of all TB
cases identified in the study.
TB Screening Results
Twenty-three percent (n = 404) of the participants screened positive based on answering “yes”
to at least one of the five questions on the screening tool. Of the 404 participants screening
Fig 1. Flow Diagram of Patient Enrollment.
doi:10.1371/journal.pone.0163462.g001
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positive, 203 (50.2%) had cough for two weeks or more, 225 (55.7%) had experiencedweight
loss of three kg or more in the last four weeks, 81 (20.0%) had fever for three weeks or more,
112 (27.7%) presented with night sweats and 111 (27.5%) had been in contact with someone
known to have TB disease. Among all participants screened, 410 (23.3%) were found to have
any cough, regardless of the duration.
TB Diagnostic Testing
All 404 of the participants who screened positive for TB had at least one smear microscopy
result, of whom 43 (10.6%) were smear-positive cases. Of those who screened positive, 358
(88.6%) had a sputum culture done at the NRL of which 52 (14.5%) were positive forM. tuber-
culosis. Anterior-posterior and lateral chest radiographs were taken for 349 (86.4%) partici-
pants screening positive, of which 89 (25.5%) were classified as abnormal. (Fig 2).
Of the 1,363 participants who answered “no” to all five screening questions, 100% had at
least one sputum smear, of whom 24 (1.8%) were sputum smear-positive. Eighty-seven percent
(1,181) had cultures performedwith 44 (3.7%) positive forM. tuberculosis. Of the 1,150
(84.4%) patients who underwent a CXR, 100 (8.7%) were interpreted as abnormal.
Overall, 138 (7.8%) of 1,767 participants enrolled were diagnosedwith TB, of which 125
(90.6%) were laboratory-confirmedpulmonary TB cases. Of the lab-confirmed cases, 74 (59%)
participants had a positive Hain and/or Capilia test, of which 13 (10.4%) were diagnosed only
with Hain/Capilia and the remaining cases were diagnosedwith a combination of sputum
smear examination and or culture. Forty (29%) participants had negative sputum smear results
Table 2. Baseline Characteristics of Study Participants.
Confirmed TB Probable TB No TB Total
N (%) 125 (7.1) 13 (0.7) 1629 (92.2) 1767 (100)
Female gender, N (%) 59 (47.2) 3 (23.1) 955 (58.7) 1,017 (57.6)
Median age, y (IQR) 35 (28–41) 38 (26–44) 33 (27–41) 33 (27–41)
CD4+ cell count, cells/mm3
Median (IQR) 304 (125–532) 151 (32–272) 395 (238–568) 385 (229–563)
<200, N (%) 48 (38.7) 9 (69.2) 324 (20.0) 381 (21.7)
> = 200, N (%) 76 (61.3) 4 (30.8) 1298 (80.0) 1378 (78.4)
WHO stage
III & IV, N (%) 20 (16.4) 3 (25.0) 179 (11.3) 202 (11.7)
I & II, N (%) 102 (83.6) 9 (75.0) 1407 (88.7) 1518 (88.3)
Location
Kigali, N (%) 67 (53.6) 7 (53.8) 863 (53.0) 937 (53.0)
Outside Kigali, N (%) 58 (46.4) 6 (46.2) 766 (47.0) 830 (47.0)
Symptoms
Any cough, N (%) 64 (51.2) 9 (69.2) 337 (20.7) 410 (23.3)
Cough for 2 weeks or more, N (%) 53 (42.4) 7 (53.9) 143 (8.8) 203 (11.5)
Night sweats, N (%) 33 (26.4) 4 (30.8) 75 (4.6) 112 (6.4)
Fever, N (%) 29 (23.2) 5 (38.5) 47 (2.9) 81 (4.9)
Weight loss, N (%) 41 (32.8) 6 (46.2) 178 (11.0) 225 (12.7)
Contact with TB patient, N (%) 18 (14.6) 0 (0) 93 (5.7) 111 (6.3)
Positive TB screena, N (%) 68 (54.4) 11 (84.6) 325 (20.0) 404 (22.9)
aAnswered ‘yes’ to one of 5 questions on cough 2 weeks, weight loss of 3 kg in 4 weeks, night sweats for 3 weeks, fever for 3 weeks, contact with a
known case of TB
doi:10.1371/journal.pone.0163462.t002
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but a positive culture forM. tuberculosis. Of the 13 participants defined as probable cases of
TB, 10 (7.2%) were pulmonary and three were extra-pulmonary (one with miliary TB and two
with pleural TB). These participants with probable cases of TB had negative sputum smears
and culture (Hain test was not done). All 13 participants diagnosedwith probable TB cases pre-
sented with clinical symptoms and a chest radiograph determined to be suggestive of TB.
Operating Characteristics of the Screening Tool
Of the 404 participants who screened positive, 68 (16.8%) had laboratory-confirmedTB. Of
the 1,363 participants who screened negative, 57 (4.2%) had laboratory-confirmedTB, includ-
ing 27 with a positive culture but negative smears. The sensitivity of the national screening tool
for laboratory confirmedTB cases was 54.4% (95% CI: 45.3%–63.3%) and increased to 67.8%
(95% CI: 57.9%–76.3%) by replacing “cough for two weeks” with “any cough” and adding a
CXR to the screening tool. The specificity of the tool was 79.5% (95% CI: 77.5%–81.5%) and
decreased to 65.3% (95% CI: 62.7%–67.8%) after replacing the “cough for two weeks” with
“any cough” and adding a CXR (Table 3).
Of the 13 participants diagnosedwith probable TB, 11 (84.6%) screened positive and two
were missed using the screening tool. When combining the confirmed and probable TB cases,
the sensitivity of the national screening tool was 57.2% (95% CI: 48.5%–65.6%) and the speci-
ficity was 80.0% (95% CI: 78.0%–82.0%).
Significant differences in the performance of the tool among participant subgroups were
observed (Table 4). When stratifying by gender, the tool had sensitivity of 43.5% in women
compared to 68.4% in men and specificity of 82.6% and 76.5%, respectively. For patients with a
CD4 cell count<200 cells/mm3, the tool has sensitivity and specificity of 71.9% (95% CI:
58.5%–83.0%) and 68.8% (95% CI 63.5%–73.8%) and for patients with CD4 cell count200
46.3% (95% CI: 35.0%–57.8%) and 82.8% (95% CI: 80.6%–84.8%) respectively. Similarly, when
Fig 2. Diagnostic Testing.
doi:10.1371/journal.pone.0163462.g002
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used for patients at WHO stage III or IV the tool had a specificity of 62.6% (95% CI: 55.0%–
69.7%) compared to 82.1% (95% CI: 80.0%–84.1%) for patients withWHO stage I and II. The
highest sensitivity of 78.3% (56.3–92.5) was found among participants withWHO clinical
stage III & IV and those with a CD4+ count<200 cells/mm3 71.9% (95% CI: 58.5–83.0).
When analyzing the performance of each of the screening questions for the confirmed cases
only or when the confirmed and probable TB cases were combined, no single indicator
achieved a sensitivity of greater than 55% (Table 3). History of cough, regardless of duration,
achieved a sensitivity of 51.2%, with a specificity of 78.9% for the confirmed cases and a sensi-
tivity of 52.9%, with a specificity of 79.3% for confirmed and probable cases combined.
Cough two weeks’ duration had a sensitivity of 42.4% with a specificity of 90.8% compared
to a sensitivity of 43.5% with a specificity of 91.3% for confirmed only or confirmed and proba-
ble cases combined, respectively.
In Fig 3 receiver operating curves (ROC) are presented for confirmed cases to demonstrate
the added value of each additional symptom. “Any cough” was the strongest predictor, with an
area under the curve (AUC) of 0.65 (95% CI: 0.60–0.69); by adding weight loss, the AUC didn’t
change, and adding night sweats the AUC was 0.66 (95% CI: 0.61–0.70). The other screening
questions added little value to the operating characteristics. Fig 4 shows the receiver operating
curves for the confirmed and probable cases combined. Cough for two weeks or more was the
strongest predictor, with an AUC of 0.67 (95% CI: 0.63–0.72); by adding weight loss, the AUC
increasedmarginally to 0.68 (95% CI: 0.63–0.72), while adding night sweats increased the
AUC to 0.70 (95% CI: 0.65–0.74). By replacing cough for more than two weeks with “any
Table 3. Operating Characteristics of the National Screening Tool, by Screening Tool Element.
Sensitivity Specificity Positive Predictive Value Negative Predictive Value
125 confirmed TB cases
National screening tool 54.4 (45.3–63.3) 79.5 (77.5–81.5) 16.8 (13.3–20.8) 95.8 (94.6–96.8)
National screening tool replacing
cough 2 weeks with any cough
58.4 (49.2–67.1) 70.8 (68.5–73.0) 13.2 (10.5–16.3) 95.7 (94.4–96.8)
National screening tool and chest X-ray 63.2 (54.91–71.6) 74.2 (72.0–76.3) 15.7 (12.6–19.2) 96.4 (95.2–97.3)
National screening tool replacing
cough 2 weeks with any cough and
chest X-ray
67.8 (57.9–76.3) 65.3 (62.7–67.8) 13.3 (10.6–16.4) 96.2 (94.8–97.4)
Cough 2 weeks 42.4 (33.6–51.6) 90.8 (89.3–92.2) 26.1 (20.2–32.7) 95.4 (94.3–96.4)
Any cough 51.2 (42.1–60.2) 78.9 (76.9–80.8) 15.6 (12.2–19.5) 95.5 (94.2–96.5)
Fever 3 weeks 23.2 (16.1–31.6) 96.8 (95.9–97.6) 35.8 (25.4–47.2) 94.3 (93.1–95.4)
Night sweats 3 weeks 26.8 (19.2–35.6) 95.2 (94.0–96.2) 29.5 (21.2–38.8) 94.5 (93.3–95.6)
Contact with TB case 14.6 (8.9–22.1) 94.3 (93.1–95.4) 16.2 (9.9–24.4) 93.6 (92.3–94.8)
Weight loss 3 kg in 4 weeks 32.8 (24.7–41.8) 88.8 (87.1–90.3) 18.2 (13.4–23.9) 94.5 (93.3–95.6)
138 confirmed and probable TB cases
National screening toola 57.2 (48.5–65.6) 80.0 (78.0–82.0) 19.6 (15.8–23.8) 95.7 (94.5–96.7)
National screening tool replacing
cough 2 weeks with any cough
60.9 (52.2–69.1) 71.3 (69.0–73.5) 15.2 (12.3–18.5) 95.6 (94.2–96.6)
Cough 2 weeks 43.5 (35.1–52.2) 91.3 (89.7–92.5) 29.6 (23.4–36.3) 95.0 (93.8–96.0)
Any cough 52.9 (44.2–61.4) 79.3 (77.2–81.2) 17.8 (14.2–21.9) 95.2 (93.9–96.3)
Fever 3 weeks 24.6 (17.7–32.7) 97.1 (96.2–97.9) 42.0 (31.1–53.5) 93.9 (92.6–95.0)
Night sweats 3 weeks 27.2 (19.9–35.3) 95.4 (94.2–96.4) 33.0 (24.2–42.6) 94.0 (92.7–95.1)
Contact with TB case 13.2 (8.0–20.0) 94.3 (93.0–95.4) 16.2 (9.9–24.4) 92.8 (91.5–94.0)
Weight loss 3 kg in 4 weeks 34.1 (26.2–42.6) 89.1 (87.4–90.5) 20.9 (15.8–26.8) 94.1 (92.8–95.2)
aQuestions on cough 2 weeks, weight loss of 3 kg in 4 weeks, night sweats for 3 weeks, fever for 3 weeks, contact with a known case of TB
doi:10.1371/journal.pone.0163462.t003
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cough” the overall AUC did not change. Other screening questions added little value to the
operating characteristics.
Discussion
This study aimed to understand the performance of the Rwandan national TB screening tool
among PLHIV enrolling in out-patient HIV care and treatment settings. During the study
enrollment period in 2011, WHO published updated guidelines for intensified TB case finding
among PLHIV, which recommend a four-element symptom-based screening tool consisting of
any current cough, fever, night sweats, or weight loss.[10] The 54.4% sensitivity of the Rwan-
dan national screening tool for confirmedTB cases was much lower than that of theWHO rec-
ommended tool (78.9%).[11] Although the NPV of 95.8% was only slightly lower than that of
theWHO-recommended tool, the overall performance of the Rwandan tool was poor in com-
parison with international normative guidance. These findings support revision of the national
TB screening tool to adapt it to theWHO recommended tool and take out the temporality of
symptoms which was undertaken in 2012.
TB screening tools are developed to have a high sensitivity and negative predictive value to
identify people suspected of having TB who require additional diagnostic testing and avoid
false negatives.[10] Screening tools can allow for many false positives as confirmatory testing is
typically part of the clinical algorithm. In this evaluation, the national screening tool showed a
low sensitivity (54.4%), and specificity (79.5%). Fifty-nine participants who screened negative
were later diagnosedwith confirmed or probable TB. However, the tool had a high NPV
(95.8% for confirmed and probable TB), indicating that absence of all of the components of the
tool can select a subset of PLHIV who have low probability of having TB disease and in whom
isoniazid preventive therapy can be initiated once TB is excluded.
The overall prevalence of TB in PLHIV newly enrolled in HIV care and treatment in this
study was higher (7.8%) than expected based on routine monitoring and evaluation data from
Rwanda. Routine programmatic data from Rwandan HIV care and treatment clinics since
2006 suggest a prevalence of TB disease of about 2% among PLHIV.[12] The higher observed
prevalence in this study is probably due to a combination of factors, including the additional
Table 4. Operating Characteristics of the National TB Screening Tool Stratified by Participant and Facility Characteristics for Confirmed and
Probable TB Cases Combined.
Sensitivity % (95% CI) Specificity % (95% CI) Positive Predictive Value % (95% CI) Negative Predictive Value % (95% CI)
Location:
Kigali 63.5 (51.5–74.4) 85.3 (82.7–87.6) 27.0 (20.6–34.3) 96.5 (94.9–97.7)
Outside of Kigali 50.0 (37.2–62.8) 74.2 (70.9–77.2) 13.9 (9.72–19.1) 94.7 (92.6–96.3)
Health facility
Hospitals 58.3 (47.8–68.3) 77.5 (74.9–80.0) 19.2 (14.8–24.2) 95.3 (93.7–96.6)
Health Centers 51.3 (34.8–67.6) 87.3 (83.3–90.5) 30.8 (19.9–43.4) 94.2 (91.1–96.5)
Gender
Male 68.4 (56.7–78.6) 76.5 (73.1–79.6) 24.8 (19.1–31.2) 95.5 (93.5–97.1)
Female 43.5 (31.0–56.7) 82.6 (80.1–85.0) 14.0 (9.43–19.7) 95.8 (94.1–97.0)
CD4+ count
< 200 cells/mm3 71.9 (58.5–83.0) 68.8 (63.5–73.8) 28.9 (21.6–37.1) 93.3 (89.4–96.1)
 200 cells/mm3 46.3 (35.0–57.8) 82.8 (80.6–84.8) 14.2 (10.2–19.1) 96.2 (94.8–97.2)
WHO stage
III & IV 78.3 (56.3–92.5) 62.6 (55.0–69.7) 21.2 (13.1–31.4) 95.7 (90.3–98.6)
I & II 54.1 (44.3–63.6) 82.1 (80.0–84.1) 19.3 (15.1–24.1) 95.8 (94.5–96.8)
doi:10.1371/journal.pone.0163462.t004
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diagnostic testing performed regardless of screening results, as well as likely under-reporting
and incomplete diagnostic workup for people suspected of having TB under routine program-
matic circumstances. However, the prevalence was comparable to what has been reported for
PLHIV in similar settings. Authors of a meta-analysis which informed the development of the
WHO-recommended screening tool for TB in PLHIV reported that based on 12 studies with
8,148 patients in resource constrained settings the overall prevalence of TB disease among
PLHIV was 5.8% (557/9,626), ranging from 0.4% to 25.7%.[11] The higher prevalence of TB
disease among PLHIV in this study indicates the need for better screening algorithms, use of
more sensitive and rapid TB diagnostics such as GeneXpert, along with robust linkages to TB
services.[13]
The proportion of probable pulmonary TB and extra-pulmonary cases was lower than
expected in a population newly enrolled in HIV care.[14,15] It has been well documented that
as immunosuppression progresses, commensurate with CD4+ cell count decline, the propor-
tion of smear negative pulmonary TB and extra-pulmonaryTB cases increases. In this sample,
patients initially had relatively high median CD4+ cell counts (385 cells/mm3). For participants
with confirmedTB, the proportion with CD4+ cell count200 cells/mm3 was 61.3%, while in
smear negative and extra-pulmonary (probable) TB the proportion was 30.8%. The low pro-
portion of smear-negative pulmonary tuberculosis and extra-pulmonary tuberculosis cases
observed in this study may be a function of participants registering for HIV care when CD4+
cell counts were relatively high and that nearly 90% of the study population had a WHO
Fig 3. Receiver Operating Curves (ROC) with Area under the Curve (AUC) for each component of the
screening tool with any cough and chest x-ray for confirmed cases only (n = 125). Dark blue: Any cough,
red: Any Cough + weight loss, green: Any Cough + weight loss + night sweats3 weeks, orange: Any Cough
+ weight loss + night sweats3 weeks + fever3 weeks, light bleu: Any Cough + weight loss + night sweats3
weeks +s fever3 weeks + known TB contact, F: any cough + weight loss + night sweats3 weeks + fever3
weeks + TB contact + x-ray.
doi:10.1371/journal.pone.0163462.g003
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clinical staging of I or II. Also of note, the HIV program in Rwanda has matured as evidenced
by the national trend of increasingmedian baseline CD4+ cell counts in patients enrolling in
HIV care.[16]
Of the different components of the screening tool, cough for two weeks or more was the
strongest predictor of TB (AUC 0.67). This is mainly due to the fact that most of the cases were
pulmonary TB (98%). Cough for two weeks or more as a single symptom was poorly sensitive
consistent with earlier studies conducted in Ethiopia, Zimbabwe and South East Asia.
[17,18,19] Using the symptom “any cough” instead of “cough for two weeks or more”
improved the sensitivity of the tool in all settings but remained lower than expected. In some
earlier studies, using a combination of symptoms and removing the temporality of all the
symptoms (e.g. remove two weeks and replace with any time period) increased the overall sen-
sitivity of the screening tool to more than 90%.[19,20] In our study, we observed a marginal
difference in sensitivity by adding the other screening questions; however, this may be due to
the fact that we only removed temporality for the cough component, while all other symptom
components required three or four weeks duration to be recorded as positive.
Changing cough of two weeks or more to any cough and adding the results of the chest X-
ray improved sensitivity of the tool from 54.4% to 67.8%. However, the specificity dropped to
65.3% and PPV to 13.3% while the negative predictive value remained high at 96.2%. These
results are similar to other published reports, although there were variations in screening tool
components and populations screenedwithin the studies.[11] The added value of the chest x-
Fig 4. Receiver Operating Curves (ROC) with Area under the Curve (AUC) for each component of the
screening tool for confirmed and probable cases (n = 138). Dark blue: Cough2 weeks, brown: Cough2
weeks + weight loss, green: Cough2 weeks + weight loss + night sweats3 weeks, orange: Cough2 weeks
+ weight loss + night sweats3 weeks + fever3 weeks, light blue: Cough2 weeks + weight loss + night sweats
3 weeks + fever3 weeks + known TB contact, red: Cough2 weeks + weight loss + night sweats3 weeks
+ fever3 weeks + TB contact.
doi:10.1371/journal.pone.0163462.g004
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ray in our study was only determined in confirmed cases (because a suggestive x-ray was part
of the definition of probable TB case, which would artificially inflate the sensitivity). In this
study we observed an 8.8% increase in sensitivity from 54.4% to 63.2% in confirmed cases of
TB after adding chest X-ray findings to the national screening tool. This increase is consistent
with the 11.7% increase noted from a meta-analysis including 12 studies and over 8,000 partici-
pants where the authors analyzed the yield of adding chest radiography to a four symptom
screen (i.e., current cough, fever night sweats and weight loss) for screening for TB disease.[11]
The NPV of the national tool was high which made the tool appropriate for excluding active
TB prior to initiation of IPT. This was also observed in other studies in Ethiopia, Zimbabwe
and South East Asia.[16,18,19] However, replacing “cough for two weeks or more” by “any
cough” and adding a chest X-ray resulted in a marginal increase in the NPV of 0.4% (from
95.8% to 96.2%).
This study had several limitations. There was initial training and periodic supervision of
study nurses however variability in use of the screening tool within and across sites was not sys-
tematically evaluated. The screening tool may not have been applied consistently and uni-
formly across sites. Also, although temporality of cough was removed for the analysis of the
additional yield for screening, this was not recorded for other screening components (fever,
night sweats and weight loss) as recommended by theWHO guidelines for intensified TB case
finding that were issued after our evaluation protocol was implemented.7 Unfortunately
because of stock-outs at the NRL, study staff were unable to performHain and/or Capilia on all
samples. In addition, cultures were done on solid media in accordance with national guidelines
which is known to be less sensitive than culture performed using liquid media.[20]
Overall, the Rwandan TB screening tool that included temporal parameters performed
poorly compared with the predicted performance of theWHO-recommended screening ques-
tions. This finding reinforces the current international recommendations—and current,
revised Rwandan national guidelines—to assess for the presence and not the duration of symp-
toms when screening for TB among PLHIV. Also, our study demonstrates the importance of
routine TB screening among PLHIV. Using a screening tool with relatively poor operating
characteristics we were still able to document a TB prevalence among PLHIV that was 65 times
greater than what is observed in the general population in Rwanda.
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